Identification
- Summary
Prochlorperazine is a phenothiazine derivative used in the treatment of schizophrenia and anxiety and to relieve severe nausea and vomiting.
- Brand Names
- Compazine, Compro
- Generic Name
- Prochlorperazine
- DrugBank Accession Number
- DB00433
- Background
Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.Label It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.9 Prochlorperazine was first developed in the 1950s 11 and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.10
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Prochlorperazine (DB00433)
- Weight
- Average: 373.943
Monoisotopic: 373.13794618 - Chemical Formula
- C20H24ClN3S
- Synonyms
- 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
- 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
- 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
- 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
- Capazine
- Chlormeprazine
- Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
- Chloropernazine
- N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
- Prochlorperazin
- Prochlorpérazine
- Prochlorperazine
- Prochlorperazinum
- Prochlorpermazine
- Prochlorpromazine
- Procloperazine
- Proclorperazina
- External IDs
- Bayer A 173
- RP 6140
- SKF 4657
Pharmacology
- Indication
Indicated for the symptomatic treatment of severe nausea and vomiting.Label
Indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.Label,8
Off-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.9
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acute migraine Combination Product in combination with: Caffeine (DB00201), Indomethacin (DB00328) •••••••••••• •••••••••••• •••••• Management of Schizophrenia •••••••••••• ••••••••• Used in combination to treat Tension headache Combination Product in combination with: Indomethacin (DB00328), Caffeine (DB00201) •••••••••••• •••••••••••• •••••• Management of Non-psychotic generalized anxiety •••••••••••• Management of Severe nausea and vomiting •••••••••••• ••••• •••••••••• ••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Prochlorperazine is an antipsychotic agent that works to promote postsynaptic inhibition of dopaminergic neurons.10 It also exerts its anti-emetic actions via anti-dopaminergic effects, where it displays similar efficacy as ondansteron, a 5HT-3 receptor antagonist and anti-emetic, in preventing delayed nausea and vomiting.3 Prochlorperazine was shown to inhibit histaminergic, cholinergic and alpha-1 adrenergic receptors.1,9 The blockade of alpha-1 adrenergic receptors may result in sedation, muscle relaxation, and hypotension. It displays anti-anxiety effects as well.10 Compared to other phenothiazine derivatives, prochlorperazine is less sedating and has a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.12 Other than its primary action on D2 receptors, one study showed that prochlorperazine may inhibit the P2X7 receptor in human macrophages, leading to inhibition of calcium ion influx.9
- Mechanism of action
The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its anti-dopaminergic effects. Prochlorperazine blocks the D2 dopamine receptors in the brain, which are somatodendritic autoreceptors. Inhibition of D2 receptor signaling results in the blockade of postsynaptic dopamine receptors in the mesolimbic system 11 and an increased dopamine turnover. Nausea and vomiting are proposed to arise from peripheral or central stimulation of serotonin type 3 (5-HT3) and dopamine type 2 receptors, the predominant receptors expressed at the chemoreceptor trigger zone (CTZ).6,11 Prochlorperazine exerts antiemetic effects and was shown to inhibit apomorphine-induced vomiting by blocking D2 dopamine receptors in the CTZ.3.
Target Actions Organism ADopamine D2 receptor antagonistHumans UHistamine H1 receptor antagonistHumans UAlpha-1 adrenergic receptors antagonistHumans NAlpha-2 adrenergic receptors antagonistHumans - Absorption
Following oral administration, prochlorperazine is reported to be well absorbed from the gastrointestinal tract. The onset of pharmacological action is about 30 to 40 minutes following oral administration and 10 to 20 minutes following intramuscular administration. The duration of action for all routes is about 3 to 4 hours.12 Following oral administration in healthy volunteers, the mean oral bioavailability was about 12.5%. In these patients, the time to reach the peak plasma concentrations was about 5 hours. Repeated oral dosing resulted in an accumulation of prochlorperazine and its metabolite. Following multiple twice daily dosing, the steady state of prochlorperazine was reached by 7 days.1
- Volume of distribution
In a preliminary pharmacokinetic study involving healthy volunteers, the mean apparent volume of distribution following intravenous administration of 6.25 mg and 12.5 mg prochlorperazine were approximately 1401 L and 1548 L, respectively.4 Prochlorperazine is reported to be distributed to most body tissues with high concentrations being distributed into liver and spleen.12 There is evidence that phenothiazines are excreted in the breast milk of nursing mothers.Label
- Protein binding
There is limited data on protein binding of prochlorperazine.
- Metabolism
Prochlorperazine undergoes hepatic metabolism involving oxidation, hydroxylation, demethylation, sulfoxide formation and conjugation with glucuronic acid.13 The oxidation reaction is mediated by CYP2D6.3 N-desmethyl prochlorperazine was detected in the plasma1, as well as prochlorperazine sulfoxide, prochlorperazine 7-hydroxide and prochlorperazine sulfoxide 4'-N-oxide, following oral and buccal administration.5 Prochlorperazine may enter the enterohepatic circulation.12
Hover over products below to view reaction partners
- Route of elimination
Prochlorperazine is reported to be mainly excreted via the feces and bile.12 Low quantities of unchanged prochlorperazine and its metabolite were detectable in the urine.1
- Half-life
Following intravenous and single oral dose administration, the terminal elimination half live were 9 and 8 hours, respectively.1
- Clearance
The mean plasma clearance (CL) of prochlorperazine following intravenous administration in healthy volunteers was approximately 0.98L/h x kg. The mean renal clearance was about 23.6 mL/h.1
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
LD50 and Overdose
Oral LD50 in rats is 750 mg/kg. Intraperitoneal and subcutaneous LD50 in mice are 191 mg/kg and 320 mg/kg, respectively.MSDS In placebo-controlled trials, there were increased incidences of mortality in elderly patients with dementia-related psychosis receiving antipsychotic medications. The risk of death in drug-treated patients was about 1.6 to 1.7 times that of placebo-treated patients. Deaths were largely resulting from cardiovascular, such as heart failure and sudden death, or infectious, such as pneumonia, conditions.Label Due to its antagonist action on dopamine receptors, prochlorperazine is associated with a risk for developing extrapyramidal symptoms such as tardive dyskinesia, which is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements. This risk is also conferred on other antipsychotic agents that block dopamine receptors. It is proposed that increased duration of the drug treatment is likely thus increased total cumulative dose of antipsychotic drugs administered to the patient leads to increased risk for developing the syndrome and the likelihood that it will become irreversible. As with other antipsychotic agents, prochlorperazine is associated with a risk for causing neuroleptic malignant syndrome (NMS), which is a potentially fatal symptom complex, which is manifested as hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability.
There is no known antidote for prochlorperazine thus overdose treatment should be supportive and symptomatic. Overdose of prochlorperazine may produce dystonic reactions that involve extrapyramidal mechanism. To reduce these symptoms, antiparkinsonism drugs, barbiturates, or diphenhydramine may be used. Symptoms of central nervous system depression, such as somnolence or coma, may also be observed. Amphetamine, destroamphetamine, or caffeine and sodium benzoate may be used to induce stimulatory effects. In contrast, agitation and restlessness may also be seen in case of overdose. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever, and autonomic reactions such as hypotension, dry mouth and ileus. Hypotension can be responded with the standard measures for managing circulatory shock.Label
Nonclinical Toxicology
In a rat developmental or reproductive toxicity study, abnormalities in both the reproductive measures and neurobehavioral testing were observed following administration of 25 mg/kg of prochlorperazine.13
Use in specific populations
As the use of antipsychotic agents during the third trimester of pregnancy is associated with a risk for extrapyramidal and/or withdrawal symptoms following delivery, the use of prochlorperazine in pregnant patients is generally not recommended and it should be limited after careful consideration of the potential benefit of drug therapy justifying the potential risk to the fetus. Caution should be exercised when prochlorperazine is administered to a nursing mother. While lower doses of prochlorperazine is reported to be safe for elderly patients, caution is still advised, especially those with higher susceptibility to hypotension and neuromuscular reactions.Label
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Prochlorperazine is combined with 1,2-Benzodiazepine. Abametapir The serum concentration of Prochlorperazine can be increased when it is combined with Abametapir. Abatacept The metabolism of Prochlorperazine can be increased when combined with Abatacept. Abiraterone The metabolism of Prochlorperazine can be decreased when combined with Abiraterone. Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Prochlorperazine. - Food Interactions
- Avoid alcohol. The drug may intensify or prolong the action of central nervous system depressants.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Prochlorperazine edisylate PG20W5VQZS 1257-78-9 SWOUGRBFXFILIB-UHFFFAOYSA-N Prochlorperazine maleate I1T8O1JTL6 84-02-6 DSKIOWHQLUWFLG-SPIKMXEPSA-N Prochlorperazine mesilate 531SH87H9N 51888-09-6 BTOOUKJFDLARFG-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Buccastem (Reckitt Benckiser) / Emetiral (Zentiva) / Stemzine (Sanofi-Aventis) / Volimin (Chin Teng)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Compazine Injection, solution 5 mg/1mm Intramuscular; Intravenous GlaxoSmithKline 2006-05-11 2006-05-11 US 
Compazine Tablet, coated 5 mg/1 Oral Glaxosmithkline Inc 2006-02-02 2011-02-11 US Compazine Capsule, extended release 10 mg/1 Oral GlaxoSmithKline 2006-05-11 2006-05-11 US Compazine Tablet, coated 5 mg/1 Oral Physicians Total Care, Inc. 1956-10-23 2004-12-31 US Compazine Suppository 5 mg/1 Rectal GlaxoSmithKline 2006-05-11 2006-05-11 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Compazine Tablet, film coated 10 mg/1 Oral Pbm Pharmaceuticals Inc. 2014-04-01 2016-01-31 US Compazine Tablet, film coated 5 mg/1 Oral Pbm Pharmaceuticals Inc. 2014-04-01 2015-12-31 US Compazine Suppository 25 mg/1 Rectal Pbm Pharmaceuticals Inc. 2013-07-01 Not applicable US Compro Suppository 25 mg/1 Rectal Padagis US LLC 2000-09-01 Not applicable US Compro Suppository 25 mg/1 Rectal A-S Medication Solutions 2000-09-01 2019-11-30 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DIFMETRE Prochlorperazine maleate (4 mg) + Caffeine (75 mg) + Indomethacin (25 mg) Suppository Mylan Italia S.R.L. 2014-07-08 Not applicable Italy 
DIFMETRE Prochlorperazine maleate (2 mg) + Caffeine (75 mg) + Indomethacin (25 mg) Tablet Viatris Italia S.R.L. 2014-07-08 2023-10-01 Italy DIFMETRE Prochlorperazine maleate (2 mg) + Caffeine (75 mg) + Indomethacin (25 mg) Tablet Mylan Italia S.R.L. 2014-07-08 Not applicable Italy DIFMETRE Prochlorperazine maleate (8 mg) + Caffeine (150 mg) + Indomethacin (50 mg) Suppository Mylan Italia S.R.L. 2014-07-08 Not applicable Italy DIFMETRE Prochlorperazine maleate (2 mg) + Caffeine (75 mg) + Indomethacin (25 mg) Tablet Mylan Italia S.R.L. 2014-07-08 Not applicable Italy
Categories
- ATC Codes
- N05AB04 — Prochlorperazine
- Drug Categories
- Antiemetics
- Antipsychotic Agents
- Antipsychotic Agents (First Generation [Typical])
- Autonomic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Substrates
- Dopamine Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Drugs causing inadvertant photosensitivity
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Moderate Risk QTc-Prolonging Agents
- Nervous System
- Neurotoxic agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Phenothiazines
- Phenothiazines With Piperazine Structure
- Photosensitizing Agents
- Psycholeptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Schizophrenia
- Sulfur Compounds
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiazines
- Sub Class
- Phenothiazines
- Direct Parent
- Phenothiazines
- Alternative Parents
- Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Benzenoids / Aryl chlorides / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides show 1 more
- Substituents
- 1,4-diazinane / Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Aryl thioether / Azacycle / Benzenoid / Diarylthioether show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- phenothiazines, organochlorine compound, N-alkylpiperazine, N-methylpiperazine (CHEBI:8435)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- YHP6YLT61T
- CAS number
- 58-38-8
- InChI Key
- WIKYUJGCLQQFNW-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
- IUPAC Name
- 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
- SMILES
- CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
References
- Synthesis Reference
- US2902484
- General References
- Isah AO, Rawlins MD, Bateman DN: Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84. [Article]
- Isah AO, Rawlins MD, Bateman DN: The pharmacokinetics and effects of prochlorperazine in elderly female volunteers. Age Ageing. 1992 Jan;21(1):27-31. doi: 10.1093/ageing/21.1.27. [Article]
- Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JW, Guchelaar HJ: Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm. 2011 Feb;33(1):33-43. doi: 10.1007/s11096-010-9454-1. Epub 2011 Jan 28. [Article]
- Taylor WB, Bateman DN: Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987 Feb;23(2):137-42. doi: 10.1111/j.1365-2125.1987.tb03021.x. [Article]
- Finn A, Collins J, Voyksner R, Lindley C: Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. J Clin Pharmacol. 2005 Dec;45(12):1383-90. doi: 10.1177/0091270005281044. [Article]
- O'Brien C: Nausea and vomiting. Can Fam Physician. 2008 Jun;54(6):861-3. [Article]
- Prochlorperazine Tablets BP 5mg - Summary of Product Characteristics [Link]
- Prochlorperazine - FDA Approval Package [Link]
- Prochlorperazine - StatPearls - NCBI Bookshelf [Link]
- Prochlorperazine - LiverTox - NIH [Link]
- Prochlorperazine — the forgotten antiemetic - UF Health [Link]
- Prochlorperazine Prescribing Information - AA Pharma [Link]
- Prochlorperazine - National Library of Medicine HSDB Database [Link]
- External Links
- Human Metabolome Database
- HMDB0014577
- KEGG Drug
- D00493
- KEGG Compound
- C07403
- PubChem Compound
- 4917
- PubChem Substance
- 46509018
- ChemSpider
- 4748
- BindingDB
- 78434
- 8704
- ChEBI
- 8435
- ChEMBL
- CHEMBL728
- ZINC
- ZINC000019796018
- Therapeutic Targets Database
- DAP000373
- PharmGKB
- PA451114
- PDBe Ligand
- P77
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Prochlorperazine
- PDB Entries
- 3m0w
- FDA label
- Download (294 KB)
- MSDS
- Download (24 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline
- Paddock laboratories inc
- Able laboratories inc
- G and w laboratories inc
- Alpharma us pharmaceuticals division
- Morton grove pharmaceuticals inc
- Baxter healthcare corp anesthesia and critical care
- Bedford laboratories div ben venue laboratories inc
- Hospira inc
- Marsam pharmaceuticals llc
- Smith and nephew solopak div smith and nephew
- Teva parenteral medicines inc
- Watson laboratories inc
- Wyeth ayerst laboratories
- Duramed pharmaceuticals inc sub barr laboratories inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Mylan pharmaceuticals inc
- Sandoz inc
- Teva pharmaceuticals usa
- Cadista pharmaceuticals inc
- Packagers
- Apotheca Inc.
- A-S Medication Solutions LLC
- Barr Pharmaceuticals
- Baxter International Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- Bryant Ranch Prepack
- Cadista Pharmaceuticals Inc.
- Cardinal Health
- Comprehensive Consultant Services Inc.
- Corepharma LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- G & W Labs
- General Injectables and Vaccines Inc.
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hospira Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- Liberty Pharmaceuticals
- Medisca Inc.
- Medvantx Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Paddock Labs
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- Patient First Corp.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharma Pac LLC
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Sandhills Packaging Inc.
- Sandoz
- Southwood Pharmaceuticals
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Dosage Forms
Form Route Strength Capsule, extended release Oral 10 mg/1 Capsule, extended release Oral 15 mg/1 Injection, solution Intramuscular; Intravenous 5 mg/1mm Suppository Rectal 2.5 mg/1 Suppository Rectal 5 mg/1 Syrup Oral 5 mg/5mL Tablet, coated Oral 10 mg/1 Tablet, coated Oral 5 mg/1 Suppository Tablet Injection Intramuscular; Intravenous Suppository Rectal 10 mg Suppository Rectal 10 mg / sup Tablet Oral Tablet Oral 10 mg Suppository Rectal 25 mg/1 Injection Intramuscular 5 mg/1mL Injection Intramuscular; Intravenous 5 mg/1mL Injection, solution Intramuscular; Intravenous 5 mg/1mL Tablet Oral 10 mg/1 Tablet Oral 5 mg/61 Tablet Oral 5 mg/1 Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 5 mg/1 Liquid Intramuscular; Intravenous 5 mg / mL Solution Intramuscular; Intravenous 5 mg / mL Tablet, coated Oral 5 MG Injection Intramuscular 12.5 mg/ml Syrup Oral 5 mg / 5 mL Tablet Oral 5 mg - Prices
Unit description Cost Unit Prochlorperazine mal powder 4.77USD g Compazine 25 mg suppository 4.25USD suppository Prochlorperazine 25 mg suppository 3.13USD suppository Compro 25 mg suppository 3.05USD suppository Compazine 5 mg tablet 1.82USD tablet Compazine 10 mg tablet 1.8USD tablet Prochlorperazine 5 mg/ml vial 1.22USD ml Prochlorperazine 5 mg/ml 0.91USD ml Prochlorperazine Maleate 10 mg tablet 0.88USD tablet Sandoz Prochlorperazine 10 mg Suppository 0.87USD suppository Prochlorperazine 10 mg tablet 0.85USD tablet Prochlorperazine Maleate 5 mg tablet 0.59USD tablet Prochlorperazine 5 mg tablet 0.57USD tablet Apo-Prochlorazine 10 mg Tablet 0.21USD tablet Apo-Prochlorazine 5 mg Tablet 0.17USD tablet Novamine 15% iv solution 0.09USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 228 °C PhysProp water solubility 15 mg/L (at 24 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 4.88 HANSCH,C ET AL. (1995) logS -4.4 ADME Research, USCD pKa 8.1 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.011 mg/mL ALOGPS logP 4.67 ALOGPS logP 4.38 Chemaxon logS -4.5 ALOGPS pKa (Strongest Basic) 7.99 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 9.72 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 109.81 m3·mol-1 Chemaxon Polarizability 41.77 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9821 Blood Brain Barrier + 0.9781 Caco-2 permeable + 0.7729 P-glycoprotein substrate Substrate 0.8537 P-glycoprotein inhibitor I Inhibitor 0.817 P-glycoprotein inhibitor II Inhibitor 0.8577 Renal organic cation transporter Inhibitor 0.7615 CYP450 2C9 substrate Non-substrate 0.7702 CYP450 2D6 substrate Non-substrate 0.5179 CYP450 3A4 substrate Non-substrate 0.5346 CYP450 1A2 substrate Inhibitor 0.9376 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Inhibitor 0.9723 CYP450 2C19 inhibitor Inhibitor 0.8994 CYP450 3A4 inhibitor Non-inhibitor 0.7676 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8557 Ames test Non AMES toxic 0.8999 Carcinogenicity Non-carcinogens 0.9456 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.3496 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8165 hERG inhibition (predictor II) Inhibitor 0.786
Spectra
- Mass Spec (NIST)
- Download (10.4 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 191.4314913 predictedDarkChem Lite v0.1.0 [M-H]- 182.99648 predictedDeepCCS 1.0 (2019) [M+H]+ 191.8553913 predictedDarkChem Lite v0.1.0 [M+H]+ 185.35448 predictedDeepCCS 1.0 (2019) [M+Na]+ 191.3826913 predictedDarkChem Lite v0.1.0 [M+Na]+ 191.44762 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Roberge RJ: Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch. J Emerg Med. 2006 Apr;30(3):299-302. [Article]
- Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [Article]
- Vinson DR: Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. J Emerg Med. 2006 Aug;31(2):139-45. [Article]
- Callan JE, Kostic MA, Bachrach EA, Rieg TS: Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5. [Article]
- Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol. 2008 Dec 14;600(1-3):105-9. doi: 10.1016/j.ejphar.2008.10.030. Epub 2008 Oct 21. [Article]
- Golembiewski J, Tokumaru S: Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- This binding interaction is theoretical based on the actions of the phenothiazine drug class and requires further investigation.
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Isah AO, Rawlins MD, Bateman DN: Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- This binding interaction is theoretical based on the actions of the phenothiazine drug class and requires further investigation.
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-1A adrenergic receptor | P35348 |
| Alpha-1B adrenergic receptor | P35368 |
| Alpha-1D adrenergic receptor | P25100 |
References
- Isah AO, Rawlins MD, Bateman DN: Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Antagonist
- Curator comments
- This binding interaction is theoretical based on the actions of the phenothiazine drug class and requires further investigation.
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-2A adrenergic receptor | P08913 |
| Alpha-2B adrenergic receptor | P18089 |
| Alpha-2C adrenergic receptor | P18825 |
References
- Isah AO, Rawlins MD, Bateman DN: Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991 Dec;32(6):677-84. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Davies SJ, Eayrs S, Pratt P, Lennard MS: Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72. doi: 10.1111/j.1365-2125.2003.02040.x. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55